Search

Your search keyword '"Moroni, Flavio"' showing total 412 results
Start Over Author "Moroni, Flavio"
412 results on '"Moroni, Flavio"'

1. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Author

Berger, Nathan, Besson, Valerie, Boulares, A, Bürkle, Alexander, Chiarugi, Alberto, Clark, Robert, Curtin, Nicola, Cuzzocrea, Salvatore, Dawson, Ted, Dawson, Valina, Haskó, György, Liaudet, Lucas, Moroni, Flavio, Pacher, Pál, Radermacher, Peter, Salzman, Andrew, Snyder, Solomon, Soriano, Francisco, Strosznajder, Robert, Sümegi, Balázs, Szabo, Csaba, and Swanson, Raymond

Subjects
Acute Disease, Animals, Chronic Disease, Drug Repositioning, Humans, Poly(ADP-ribose) Polymerase Inhibitors
Abstract

UNLABELLED: The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinsons disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors. LINKED ARTICLES: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.

Published
2018

4. Methadone Dose Adjustments, Plasma R-Methadone Levels and Therapeutic Outcome of Heroin Users : A Randomized Clinical Trial

Author

Mannaioni, Guido, Lanzi, Cecilia, Lotti, Michela, Galli, Valentina, Totti, Arianna, Pacileo, Ilaria, Sili, Maria, Pracucci, Chiara, Dilaghi, Arianna, Bertieri, Lara, Quaranta, Mariarita, Orsini, Francesco, Occupati, Brunella, Michahelles, Assia, Ciuti, Riccardo, Bianchini, Elisa, Fabbro, Giancarlo, Biggeri, Annibale, Masini, Emanuela, and Moroni, Flavio

Published
2018

23. Poly(ADP-ribosyl)ation regulates heat shock factor-1 activity and the heat shock response in murine fibroblasts

Author

Fossati, Silvia, Formentini, Laura, Wang, Zhao-Qi, Moroni, Flavio, and Chiarugi, Alberto

Subjects
Biochemistry -- Research -- Genetic aspects, Cytology -- Research -- Genetic aspects, Muridae -- Genetic aspects -- Research, Fibroblasts -- Genetic aspects -- Research, Apoptosis -- Genetic aspects -- Research, DNA polymerases -- Genetic aspects -- Research, Biological sciences, Research, Genetic aspects
Abstract

Abstract: Poly(ADP-ribose) polymerase-1 (PARP-1)-dependent poly(ADP-ribose) formation is emerging as a key regulator of transcriptional regulation, even though the targets and underlying molecular mechanisms have not yet been clearly identified. In [...]

Published
2006

31. Differential mechanisms of tolerance induced by NMDA and 3,5‐dihydroxyphenylglycine (DHPG) preconditioning

Author

Gerace, Elisabetta, primary, Zianni, Elisa, additional, Landucci, Elisa, additional, Scartabelli, Tania, additional, Berlinguer Palmini, Rolando, additional, Iezzi, Daniela, additional, Moroni, Flavio, additional, Di Luca, Monica, additional, Mannaioni, Guido, additional, Gardoni, Fabrizio, additional, and Pellegrini‐Giampietro, Domenico E., additional

Published
2020
Full Text
View/download PDF

37. Amatoxin poisoning: a 15-year retrospective analysis and follow-up evaluation of 105 patients

Author

Giannini, Lucia, Vannaci, Alfredo, Missanelli, Andrea, Mastroianni, Rosanna, Msnnsioni, Pier Francesco, Moroni, Flavio, and Masini, Emanuela

Subjects
Mycotoxicoses -- Development and progression, Mycotoxicoses -- Care and treatment, Mycotoxicoses -- Patient outcomes, Mycotoxicoses -- Case studies, Amanita -- Health aspects, Mushrooms, Poisonous -- Health aspects, Environmental issues, Health, Pharmaceuticals and cosmetics industries
Published
2007

46. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases

Author

Berger, Nathan A, Besson, Valerie C, Boulares, A Hamid, Bürkle, Alexander, Chiarugi, Alberto, Clark, Robert S, Curtin, Nicola J, Cuzzocrea, Salvatore, Dawson, Ted M, Dawson, Valina L, Haskó, György, Liaudet, Lucas, Moroni, Flavio, Pacher, Pál, Radermacher, Peter, Salzman, Andrew L, Snyder, Solomon H, Soriano, Francisco Garcia, Strosznajder, Robert P, Sümegi, Balázs, Swanson, Raymond A, and Szabo, Csaba

Subjects
Pharmacology, Neurosciences, Drug Repositioning, Evaluation of treatments and therapeutic interventions, Pharmacology and Pharmaceutical Sciences, Poly(ADP-ribose) Polymerase Inhibitors, Brain Disorders, Rare Diseases, Orphan Drug, Good Health and Well Being, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Acute Disease, Chronic Disease, Animals, Humans, Pharmacology & Pharmacy, Development of treatments and therapeutic interventions, Lung
Abstract

The recent clinical availability of the PARP inhibitor olaparib (Lynparza) opens the door for potential therapeutic repurposing for non-oncological indications. Considering (a) the preclinical efficacy data with PARP inhibitors in non-oncological diseases and (b) the risk-benefit ratio of treating patients with a compound that inhibits an enzyme that has physiological roles in the regulation of DNA repair, we have selected indications, where (a) the severity of the disease is high, (b) the available therapeutic options are limited, and (c) the duration of PARP inhibitor administration could be short, to provide first-line options for therapeutic repurposing. These indications are as follows: acute ischaemic stroke; traumatic brain injury; septic shock; acute pancreatitis; and severe asthma and severe acute lung injury. In addition, chronic, devastating diseases, where alternative therapeutic options cannot halt disease development (e.g. Parkinson's disease, progressive multiple sclerosis or severe fibrotic diseases), should also be considered. We present a preclinical and clinical action plan for the repurposing of PARP inhibitors.Linked articlesThis article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results